You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Funded Evidence-Informed Regimens

Drug and regimen monographs and information sheets for patients provide information on dosing and administering cancer treatment protocols. They are for general reference and are not meant to replace prescribing information or physician recommendations.

If you have questions about ST-QBP funding on our website, please visit our Frequently Asked Questions page.

Find enhanced Regimen Patient Information Sheets, created in collaboration with patient and family advisors.

Regimens

93 Items
Cancer Type: Breast     
Intent: Neoadjuvant, Adjuvant
Funding:
New Drug Funding Program
  • Paclitaxel - Adjuvant Treatment for Breast Cancer
New Drug Funding Program
  • Paclitaxel - Neoadjuvant Treatment for Non-Metastatic Breast Cancer
New Drug Funding Program
  • Trastuzumab - Adjuvant Treatment for HER2_neu-Overexpressing Primary Breast Cancer
Evidence Building Program
  • Trastuzumab (EBP) - Adjuvant Treatment for Breast Cancer
Evidence Building Program
  • Trastuzumab (EBP) - Adjuvant Treatment for Breast Cancer Supplemental
Jan 2019
Cancer Type: Breast     
Intent: Neoadjuvant, Adjuvant
Funding:
New Drug Funding Program
    Paclitaxel - Adjuvant Treatment for Breast Cancer
New Drug Funding Program
    Paclitaxel - Neoadjuvant Treatment for Non-Metastatic Breast Cancer
New Drug Funding Program
    Trastuzumab - Adjuvant Treatment for HER2_neu-Overexpressing Primary Breast Cancer
Evidence Building Program
    Trastuzumab (EBP) - Adjuvant Treatment for Breast Cancer
Evidence Building Program
    Trastuzumab (EBP) - Adjuvant Treatment for Breast Cancer Supplemental
Feb 2018
Cancer Type: Breast     
Intent: Neoadjuvant, Adjuvant
Funding:
New Drug Funding Program
  • Trastuzumab - Adjuvant Treatment for HER2_neu-Overexpressing Primary Breast Cancer
Evidence Building Program
  • Trastuzumab (EBP) - Adjuvant Treatment for Breast Cancer
Evidence Building Program
  • Trastuzumab (EBP) - Adjuvant Treatment for Breast Cancer Supplemental
New Drug Funding Program
  • Paclitaxel - Adjuvant Treatment for Breast Cancer
New Drug Funding Program
  • Paclitaxel - Neoadjuvant Treatment for Non-Metastatic Breast Cancer
Feb 2017
Cancer Type: Gynecologic, Germ Cell     
Intent: Curative
May 2019
Cancer Type: Genitourinary, Testis     
Intent: Curative
May 2019
Cancer Type: Genitourinary, Bladder / Urothelial     
Intent: Adjuvant, Palliative
Jun 2019
Cancer Type: Genitourinary, Testis     
Intent: Palliative
Jan 2018
Cancer Type: Gynecologic, Ovary     
Intent: Adjuvant, Palliative
Funding:
New Drug Funding Program
    Paclitaxel in Combination with Platinum - First Line - Advanced Ovarian Fallopian Tube or Primary Peritoneal Carcinoma
New Drug Funding Program
    Paclitaxel in Combination with Platinum - Recurrent - Advanced Ovarian Fallopian Tube or Primary Peritoneal Carcinoma
Aug 2017
Cancer Type: Gynecologic, Cervix     
Intent: Palliative
Apr 2016
Cancer Type: Gynecologic, Endometrial     
Intent: Adjuvant, Palliative
Funding:
New Drug Funding Program
    Paclitaxel - First Line - Uterine Papillary Serous Carcinoma (UPSC)
New Drug Funding Program
    Paclitaxel - Recurrent - Uterine Papillary Serous Carcinoma (UPSC)
Oct 2017
Cancer Type: Gynecologic, Ovary     
Intent: Adjuvant
Funding:
New Drug Funding Program
    Paclitaxel in Combination with Platinum - First Line - Advanced Ovarian Fallopian Tube or Primary Peritoneal Carcinoma
May 2019
Cancer Type: Gynecologic, Cervix     
Intent: Palliative
Funding:
New Drug Funding Program
    Bevacizumab (Biosimilar) - Metastatic (Stage IVB), Persistent, or Recurrent Carcinoma of the Cervix
Aug 2019